Clinical Trial Details
| Trial ID: | L0037 |
| Source ID: | NCT05387187 |
| Associated Drug: | Pu Yang Wan Wu Tang Plus Pentoxifylline |
| Title: | Evaluate the Effect and Safety of Pu Yang Wan Wu Tang and Western Medicine on Chronic Kidney Disease |
| Acronym: | |
| Status: | ENROLLING_BY_INVITATION |
| Study Results: | NO |
| Results: | |
| Conditions: | Chronic Kidney Diseases |
| Interventions: | DRUG: Pu Yang Wan Wu Tang plus Pentoxifylline|DRUG: Pentoxifylline |
| Outcome Measures: | Primary: Value of eGFR, At baseline|Value of eGFR, At 4-weeks|Value of eGFR, At 8-weeks|Value of eGFR, At 12-weeks | Secondary: Value of Creatinine, At baseline|Value of Creatinine, At 4-weeks|Value of Creatinine, At 8-weeks|Value of Creatinine, At 12-weeks|Value of BUN, At baseline|Value of BUN, At 4-weeks|Value of BUN, At 8-weeks|Value of BUN, At 12-weeks|Ratio of Urine Protein/Urine Creatinine, At baseline|Ratio of Urine Protein/Urine Creatinine, At 4-weeks|Ratio of Urine Protein/Urine Creatinine, At 8-weeks|Ratio of Urine Protein/Urine Creatinine, At 12-weeks|Value of GOT, At baseline|Value of GOT, At 4-weeks|Value of GOT, At 8-weeks|Value of GOT, At 12-weeks|Value of GPT, At baseline|Value of GPT, At 4-weeks|Value of GPT, At 8-weeks|Value of GPT, At 12-weeks |
| Sponsor/Collaborators: | Sponsor: Taipei Medical University Hospital |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2|PHASE3 |
| Enrollment: | 40 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2022-05-01 |
| Completion Date: | 2023-06-20 |
| Results First Posted: | |
| Last Update Posted: | 2023-06-26 |
| Locations: | Taipei Medical University, Taipei, 110, Taiwan |
| URL: | https://clinicaltrials.gov/show/NCT05387187 |
